← Back to Search

Cognitive Behavioral Therapy

Cognitive Behavioral Therapy for Post-Concussion Syndrome

N/A
Recruiting
Led By Sean Rose, MD
Research Sponsored by Sean Rose
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 0 to day 35
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if a cognitive behavioral therapy program called C-STEP can help children with ongoing concussion symptoms. The program includes education, activity management, sleep tips, and relaxation training.

Who is the study for?
This trial is for children and young adults aged 10-18 who have had a concussion between 1 to 12 months ago, are experiencing at least two post-concussion symptoms, and can commit to a treatment program. It's not for those with severe pre-injury mental illness, pregnant females, non-English speakers, or anyone unable to consent or complete the study procedures.
What is being tested?
The study is testing C-STEP (Cognitive Behavioral Therapy) against usual care in improving outcomes for individuals with post-concussion syndrome. Participants will be randomly assigned to one of these treatments to compare effectiveness.
What are the potential side effects?
Since C-STEP involves therapy rather than medication, side effects may include discomfort from discussing personal issues or fatigue from participation but typically do not involve physical side effects like drugs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 0 to day 35
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 0 to day 35 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change Pediatric Quality of Life Inventory, Version 4.0 (PedsQL)
Change in Sport Concussion Assessment Tool- Fifth Edition (SCAT-5) Concussion Symptoms
Secondary study objectives
Change in Auditory Attention and Working Memory
Change in Brain Connectivity
Change in Cognitive Flexibility
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Usual Care + C-STEPExperimental Treatment2 Interventions
Usual care in the NCH Complex Concussion Clinic, plus 4 weekly sessions of C-STEP
Group II: Usual CareActive Control1 Intervention
Usual care in the NCH Complex Concussion Clinic
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Usual Care
1990
Completed Phase 4
~7700

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Post-Concussion Syndrome (PCS) include cognitive behavioral therapy (CBT), pharmacotherapy, and physical rehabilitation. CBT works by helping patients reframe negative thought patterns and develop coping strategies, which can alleviate symptoms such as anxiety, depression, and cognitive impairments. Pharmacotherapy may involve medications like SSRIs or SNRIs to manage mood disorders, while physical rehabilitation focuses on improving balance and reducing dizziness. Understanding these mechanisms is crucial for PCS patients as it allows for targeted treatment plans that address specific symptoms, ultimately improving their quality of life and aiding in recovery.
Physical Activity and Intermittent Postconcussion Symptoms After a Period of Symptom-Limited Physical and Cognitive Rest.

Find a Location

Who is running the clinical trial?

Sean RoseLead Sponsor
Nationwide Children's HospitalOTHER
348 Previous Clinical Trials
5,228,029 Total Patients Enrolled
Ohio State UniversityOTHER
866 Previous Clinical Trials
655,084 Total Patients Enrolled
~1 spots leftby Dec 2024